Acalabrutinib comment watch save
BreastfeedingPediatric

  • FDA APPROVAL DATE: 10/31/2017
  • CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
    Antacids, Famotidine, H2-receptor antagonists, Itraconazole, Proton pump inhibitors, Ranitidine, Rifampin, Strong CYP3A inducers, Strong or moderate CYP3A inhibitors
  • PREGNANCY: May cause fetal toxicity based on findings in animal studies

Please login to view the rest of this drug profile.

Page last updated 10/29/2024

Symbol key

Incidence

<1% 1‑5% 5‑10% 10‑15% 15‑20% 20‑30% >30%

Seriousness

Hospitalization possible
Life threatening
Fatal

Warnings in other populations

BreastfeedingBreast feeding

GeriatricGeriatric

PediatricPediatric

Back to top